A group of researchers has developed a innovative therapy that activates a antitumor response against him HER2+ breast cancer in preclinical models with ratolins. Specifically, it has been demonstrated that it is possible to obtain a “complete, long-lasting and safe” antitumor response through samples of patients with tumors positive for HER2 and p95HER2. The new therapy used in the study is a CAR-T of the latest generation directed at the p95HER2 protein, specifically present in a third of HER2+ tumors.
The study has been published Nature Communications I have led researchers from the Vall d’Hebron Institute of Oncology (VHIO) i de l’Hospital del Mar Research Institute (HMRIB). The first day of the quests has been sol·licitat to pose in Marx a assaig clinic to test the new mechanism in patients. The treatment has been tested in preclinical models with HER2+ tumors that present p95HER2, derived from patients.
Joaquin Arribashead of the VHIO Growth Factors Group and director of the Hospital del Mar Research Institute, recalled that the CAR-T It is an advanced cellular therapy that consists of genetically modifying the patient’s immune cells (T cells) to ensure that they attack specific targets of the tumors. The new treatment is based on a CAR-T “similar to that used in hematological diseases” on a routine basis.
As they have corroborated other investigations, the investigators will verify that the transaction had antitumor trainingbut it was not very effective in solid tumors. What has been done is taking advantage of the CAR-T’s ability to carry different therapies to increase effectiveness without compromising safety because “it does not affect non-tumor cells,” he has stated. ‘expert.
From the mouse to the clinic clinic
Above has indicated that the experimental model What will serve the laboratory will consist of implanting real tumors from breast cancer patients who are ateseses to the VHIO. “They are going to determine that if we expressly introduce tumor cells into these animals we see that they are protected, since this is one of the characteristics of the immune system,” the doctor explained.
The doctor Macarena Romanpostdoctoral researcher of the Growth Factors Group of the VHIO and the Research Institute of the Hospital del Mar, and first author of the study, has stated that in the majority of rats “the tumors of a considerable size are “They are going to reduce to the disappearance of all animals and they live without affecting the quality of life.” The answer to preclinical models is “impressive”so it will be necessary to validate results in a clinical assessment to confirm safety and effectiveness details.
Above explained that they have obtained finances to pose in Marx a phase I clinical assaig. The forecast is to be able to start it any time you see and recruit a fortnight of patients Both tumors are driven by the overexpression of the HER2 protein and that all therapeutic options have been exhausted. Since HER2 is the receptor most attacked in the development of oncological therapies, a third of advanced HER2+ breast cancer patients do not respond to these treatments.
#Researchers #Catalonia #develop #therapy #rats #activates #response #breast #cancer
